Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.

Trial Profile

Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Botulinum toxin A (Primary) ; Alpha 1 adrenergic receptor antagonists; Cholestenone 5-alpha reductase inhibitors; Herbal medicines
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Acronyms PROTOX
  • Most Recent Events

    • 24 Apr 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 21 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top